补肾益髓方预防非小细胞肺癌化疗后血小板减少症临床研究  

Clinical study of Bushen Yisui Formula in preventing chemotherapy-induced thrombocytopenia of non-small cell lung cancer

作　　者：冯海英[1] 张晓萌 德艳艳[1] 陈平[1] 王红娟[1] 刘建军[1] 李建波[2] FENG Haiying;ZHANG Xiaomeng;DE Yanyan;CHEN Ping;WANG Hongjuan;LIU Jianjun;LI Jianbo(Department of Hematology and Oncology,Huanghua Municipal People's Hospital,Huanghua,Hebei 061100;Department of Traditional Chinese Medicine,the Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei 050011)

机构地区：[1]河北省黄骅市人民医院血液肿瘤科,河北黄骅061100 [2]河北医科大学第四医院中医科,河北石家庄050011

出　　处：《河北中医》2023年第9期1454-1458,共5页Hebei Journal of Traditional Chinese Medicine

基　　金：河北省中医药管理局2020年度中医药类科研计划课题(编号:2020185);沧州市重点研发计划指导项目(编号:204106144)。

摘　　要：目的观察补肾益髓方预防非小细胞肺癌化疗后血小板减少症的疗效。方法将70例非小细胞肺癌化疗患者按照随机数字表法分为2组,每组35例,2组均接受GP方案化疗,对照组予常规促血小板生成药物治疗,治疗组在对照组基础上加补肾益髓方,于化疗前1周开始口服,连服28天。比较2组化疗前1天及化疗14、21天血小板计数(PLT)、血小板平均体积(MPV),比较2组化疗前和化疗14、21天中医症状评分、Kamofsky功能状态(KPS)评分,比较2组PLT最低值时间、PLT恢复正常值时间、重组人白介素-11用量及化疗后血小板减少症发生率。结果与本组化疗前1天相比,治疗组化疗21天时PLT明显降低(P<0.05),对照组化疗14、21天时PLT均明显降低(P<0.05)。化疗14、21天时,治疗组PLT均明显高于对照组同期(P<0.05)。化疗14、21天时,治疗组MPV未出现明显变化(P>0.05),且均高于对照组同期(P<0.05)。而对照组化疗21天时MPV较本组化疗前1天明显降低(P<0.05)。与对照组相比,治疗组PLT最低值时间明显延后(P<0.05),PLT恢复正常时间明显缩短(P<0.05),重组人白介素-11使用量明显减少(P<0.05)。化疗14、21天,治疗组中医症状评分、KPS评分均较本组化疗前无明显变化(P>0.05),而对照组中医症状评分均较本组化疗前升高(P<0.05),KPS评分均较本组化疗前显著降低(P<0.05)。化疗14、21天,治疗组中医症状评分均明显低于对照组同期(P<0.05),KPS评分均明显高于对照组同期(P<0.05)。治疗组血小板减少症发生率2.86%(1/35),对照组血小板减少症发生率22.86%(8/35),治疗组血小板减少症发生率低于对照组(P<0.05)。结论补肾益髓方可改善非小细胞肺癌化疗后患者PLT水平,防治血小板减少症的发生,维持患者生活质量。Objective To observe the clinical effect of Bushen Yisui Formula in preventing chemotherapy-induced thrombocytopenia of non-small cell lung cancer(NSCLC).Methods A total of 70 NSCLC patients were recruited and randomly allocated to the control group(n=35)and the treatment group(n=35).All patients were given Gemcitabine plus cisplatin(GP)chemotherapy.The control group was treated with conventional antiplatelet drugs,and the treatment group was additionally given oral Bushen Yisui Formula 1 week before chemotherapy,and the treatment continued for 28 days.The platelet count(PLT),mean platelet volume(MPV)1 day before chemotherapy,and at 14 and 21 days of chemotherapy,the traditional Chinese medicine(TCM)symptom scores,Karnofsky Performance Status(KPS)scores,the time to PLT minimum value and normal PLT,recombinant human interleukin 11(rhIL-11),as well as the incidence of chemotherapy-induced thrombocytopenia before chemotherapy and at 14 and 21 days of chemotherapy between groups were included as comparators.Results Compared with the group 1 day before chemotherapy,PLT in the treatment group was significantly lower at 21 days of chemotherapy(P<0.05),and PLT in the control group was significantly lower at 14 and 21 days of chemotherapy(P<0.05).PLT in the treatment group was significantly higher than that in the control group at 14 and 21 days of chemotherapy(P<0.05).There was no significant change in MPV in the treatment group between 14 and 21 days of chemotherapy(P>0.05),which was higher than that in the concurrent control group(P<0.05).In the control group,MPV at 21 days of chemotherapy was significantly lower than that at 1 day before chemotherapy(P<0.05).Compared with the control group,the time to PLT minimum value in the treatment group was significantly delayed(P<0.05),the time to normal PLT was significantly shortened(P<0.05),and the amount of rhIL-11 was significantly reduced(P<0.05).The differences in the treatment group were not significantly in the scores of TCM symptoms and KPS at 14 and 21 days of chemoth

关 键 词：癌 非小细胞肺 抗肿瘤联合化疗方案 血小板减少 中医药疗法 

分 类 号：R734.205.31[医药卫生—肿瘤] R558.2[医药卫生—临床医学]